Short Interest in PAVmed Inc. (NASDAQ:PAVM) Declines By 50.2%

PAVmed Inc. (NASDAQ:PAVM) was the recipient of a significant decline in short interest in February. As of February 27th, there was short interest totaling 49,462 shares, a decline of 50.2% from the February 12th total of 99,245 shares. Approximately 5.3% of the company’s shares are sold short. Based on an average daily trading volume, of 52,636 shares, the short-interest ratio is presently 0.9 days. Based on an average daily trading volume, of 52,636 shares, the short-interest ratio is presently 0.9 days. Approximately 5.3% of the company’s shares are sold short.

Institutional Inflows and Outflows

An institutional investor recently raised its position in PAVmed stock. Jane Street Group LLC grew its stake in shares of PAVmed Inc. (NASDAQ:PAVM) by 392.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,676 shares of the company’s stock after acquiring an additional 41,990 shares during the period. Jane Street Group LLC owned about 0.31% of PAVmed worth $32,000 at the end of the most recent quarter. 19.93% of the stock is owned by institutional investors.

PAVmed Trading Down 3.4%

NASDAQ PAVM traded down $0.36 during mid-day trading on Thursday, reaching $10.38. 29,261 shares of the company’s stock traded hands, compared to its average volume of 1,296,249. The company has a market cap of $10.17 million, a price-to-earnings ratio of -0.61 and a beta of 0.90. The company has a fifty day simple moving average of $9.28 and a 200-day simple moving average of $11.03. PAVmed has a 1-year low of $6.00 and a 1-year high of $28.44.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on PAVM shares. Ascendiant Capital Markets dropped their price objective on shares of PAVmed from $600.00 to $510.00 and set a “buy” rating for the company in a research report on Wednesday, December 10th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of PAVmed in a research report on Thursday, January 22nd. Wall Street Zen upgraded PAVmed to a “sell” rating in a report on Saturday, February 14th. Finally, Zacks Research lowered PAVmed from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $510.00.

PAVmed Company Profile

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.